Kidney protection using the RenalGuard® system in cardiac surgery
Research type
Research Study
Full title
Kidney protection using the RenalGuard® system in cardiac surgery (Kidney Study)
IRAS ID
212948
Contact name
Heyman Luckraz
Contact email
Sponsor organisation
Royal Wolverhampton NHS Trust
Clinicaltrials.gov Identifier
Duration of Study in the UK
1 years, 5 months, 20 days
Research summary
Kidney injury (AKI) is reported in up to 30% of patients undergoing cardiac surgery. One in four of these patients will also require renal replacement therapy (RRT) while in hospital. Data from our Unit as well as the literature review confirmed that there were worse patient outcomes when AKI developed. These included increased incidence of post-operative complications such as atrial fibrillation, infections (Chest and wound), confusion as well as increased intensive care and hospital stays. Moreover, there is decreased survival both at 30-day and in the longer term in patients who developed AKI after heart surgery. Finally, there is also evidence suggesting that in the longer term, the quality of life of patients who developed AKI post-cardiac surgery is worse when compared to those who did not.
The RenalGuard® System has been used successfully in patients with heart disease undergoing percutaneous coronary intervention (PCI) and trans-catheter aortic valve implantation (TAVI). It is based on the principle of forced diuresis using furosemide accompanied by minute-to-minute intravenous rehydration. It requires a urinary catheter (all patients undergoing cardiac surgery will have one) and an intravenous access for fluid.
If the RenalGuard® System is proven to be beneficial to prevent AKI in patients undergoing cardiac surgery, then it will reduce post-operative intensive care & hospital stays, complications, mortality and enable a significant cost-savings.REC name
HSC REC A
REC reference
16/NI/0246
Date of REC Opinion
2 Dec 2016
REC opinion
Further Information Favourable Opinion